Abstract
Androgen receptor blockade may have clinical utility in treating cancers other than prostate cancer. Several mouse studies have found that antiandrogen drugs boost the efficacy of immune checkpoint inhibitors and help combat resistance to targeted agents for a variety of tumor types. Clinical trials are underway to assess AR inhibition as an adjunct to multiple forms of cancer therapy.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.